Following the successive announcements of significant progress in its first-in-class antibody drug SGC001 for acute myocardial infarction and next-generation immuno-oncology pipeline SGT003, Sungen BioMed has announced another major advancement at the 2026 J.P. Morgan Healthcare Conference: the proprietary SG Linker-Payload technology platform. This versatile platform, capable of flexible combinations between novel linkers and diverse payloads, establishes a robust technological foundation for developing a diversified pipeline of antibody-drug conjugates (ADCs), marking a leap forward in the company’s core R&D capabilities.
ADCs have solidified their position at the forefront of oncology drug development by combining precise targeting with potent cytotoxic effects. The continuous evolution of ADC technology is heavily driven by optimizing the critical linker-payload system, a key focus area for overcoming traditional limitations and achieving next-generation performance.
Sungen BioMed’s research team has developed a breakthrough, highly hydrophilic linker-payload platform to address these challenges. Its core innovation lies in a unique high-hydrophilicity design that solves the common problem of molecular aggregation caused by hydrophobicity in conventional ADCs at the molecular level. This design significantly enhances overall drug stability, laying a crucial foundation for improved safety and efficacy profiles. ADCs developed on this platform demonstrate markedly superior performance in key metrics, including lower levels of free payload shedding and more consistent drug-to-antibody ratios (DAR) compared to industry standards.
The platform’s linker exhibits highly flexible conjugation adaptability, enabling efficient pairing with payloads of various mechanisms of action. This allows for rapid identification of the optimal payload strategy tailored to different tumor targets, substantially broadening the scope of ADC drug development and providing an efficient path for creating therapies against multiple targets. In preclinical pharmacodynamic studies, several ADC candidates constructed with this platform against various tumor-associated targets exhibited a “same dose, higher efficacy” profile, with tumor growth inhibition rates increased by over 30% in some animal models. These results confirm the platform’s advanced technological edge and superior efficacy, providing high-confidence data to accelerate pipeline progression and a solid foundation for clinical development.
Since its inception, Sungen BioMed has been committed to pioneering innovation, steadily building a diversified and high-value pipeline spanning cardiovascular diseases and oncology. The introduction of the “SG Linker-Payload” platform further enriches the company’s innovation matrix. Relying on its unique technical advantages, it forms deep synergy with the next-generation immuno-oncology (IO) pipeline centered on SGT003, establishing a potent dual-therapy system of “precision killing + immune activation.” This synergy paves the way for novel combination therapies with significant clinical potential for cancer patients.
Updated: Jan 26, 2026
